Tags:DevelopmentEngineeringHardwareManufacturingPlatformProductSkinTechnologyUniversityWebsite
Novadip Biosciences, a biomedical spin-off company from the University of Louvain (UCL, Belgium) and its academic hospital, (Cliniques universitaires Saint-Luc), is developing innovative solutions for critical tissue reconstruction. Using its proprietary technology platform for tissue engineering and manufacturing, Novadip is addressing the need for critical size bone and skin reconstruction in patients who currently have limited or no effective treatment options. Novadip’s first product is being tested in a phase 1/2a clinical trial in spinal fusion patients. A second product, specifically designed for large bone defects, is currently enrolling patients with non-healing bone fractures (bone non-union) in a phase 1/2a clinical trial. Novadip is also developing a regenerative skin product aimed at reconstruction of large skin defects or grafts and is using its technology platform to develop “off-the-shelf” products to address additional, larger clinical indications. Website
Total raised: $53.656469M

Investors 2

Funding Rounds 2

DateSeriesAmountInvestorsDeal News
28.10.2021Series B$22.052584...--
10.09.2015Series A$31.603885...--

Mentions in press and media 6

DateTitleDescriptionCategoryAuthorSource
28.10.2021Novadip Bi...Novadip Biosciences announces ...--fundplus.b...
28.10.2021Novadip Bi...Novadip Biosciences announces ...--marketscre...
28.10.2021Novadip Bi...Novadip Biosciences announces ...--globenewsw...
28.10.2021Novadip Bi...Novadip Biosciences announces ...--globenewsw...
10.09.2015Novadip Bi...Novadip Biosciences, a biophar...Belgium-finsmes.co...
09.09.2015Daily fund...Didi Kuaidi scored $1B; Chef b...-Mitos Suso...vator.tv/n...